following an abbreviated submission
ustekinumab (Stelara®) is accepted for restricted use within NHS Scotland.
Indication under review: treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
SMC restriction: continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.
Ustekinumab has previously been accepted for restricted use in adults for this indication. For the small number of adolescent patients weighing >100kg that require a dose of 90mg, a 90mg prefilled syringe is available at the same price as the 45mg prefilled syringe.
Download detailed advice111KB (PDF)
Medicine details
- Medicine name:
- ustekinumab (Stelara)
- SMC ID:
- 1115/15
- Indication:
- For the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Skin
- Submission type
- Abbreviated
- Status
- Superseded
- Date advice published
- 11 January 2016